| Page 1711 | Kisaco Research
 

Dr. Yoshifumi Nishikawa

Professor
Obihiro University of Agriculture and Veterinary Medicine

Dr. Yoshifumi Nishikawa

Professor
Obihiro University of Agriculture and Veterinary Medicine

Dr. Yoshifumi Nishikawa

Professor
Obihiro University of Agriculture and Veterinary Medicine
 

Mr. Zidong Lin

Assistant General Manager, Member of the Board
Nantong HiTide Biotechnology Co., Ltd

Mr. Zidong Lin

Assistant General Manager, Member of the Board
Nantong HiTide Biotechnology Co., Ltd

Mr. Zidong Lin

Assistant General Manager, Member of the Board
Nantong HiTide Biotechnology Co., Ltd
 

Dr. Kenichi Masuda

CEO
Animal Allergy Clinical Laboratories

Dr. Kenichi Masuda is CEO of Animal Allergy Clinical Laboratories, Inc., established as a RIKEN venture company since 2007. He is also a team leader of Vaccine Innovation Laboratory, RIKEN, actively developing new technologies for allergy testings, therapeutic antibody drugs, and vaccine for emerging zoonosis. One of his recent achievements in small animal medicine is to develop a novel anti-IgE antibody widely cross-reactive among animals and humans, which enables us to measure IgE only associated with allergic diseases and to eliminate IgE producing B cells.

Dr. Kenichi Masuda

CEO
Animal Allergy Clinical Laboratories

Dr. Kenichi Masuda

CEO
Animal Allergy Clinical Laboratories

Dr. Kenichi Masuda is CEO of Animal Allergy Clinical Laboratories, Inc., established as a RIKEN venture company since 2007. He is also a team leader of Vaccine Innovation Laboratory, RIKEN, actively developing new technologies for allergy testings, therapeutic antibody drugs, and vaccine for emerging zoonosis. One of his recent achievements in small animal medicine is to develop a novel anti-IgE antibody widely cross-reactive among animals and humans, which enables us to measure IgE only associated with allergic diseases and to eliminate IgE producing B cells.

He graduated from Kagoshima University, 1992, and then has engaged in small animal practice as a veterinarian for 3 years. He took a master’s degree major in veterinary medicine from The University of Illinois, 1997, and a Ph.D. degree major in veterinary science from The University of Tokyo, 2003. He used to be a member of International Task Force on Canine Atopic Dermatitis, 2004-2010, and International Committee on Allergic Diseases of Animals, 2010-2019. He is one of leading researchers on allergic diseases in dogs and cats.

 

Alfred Chua

CEO
Biovalence

Dr. Alfred Chua was awarded a Colombo Plan scholarship by the Singapore government to read Veterinary Medicine in France at the Ecole Nationale Vétérinaire de Lyon. Alfred graduated with a degree in veterinary medicine in 1989 and returned to Singapore to serve his bond with the Agri-foods and Veterinary Authority of Singapore. He also a Diplomate in Immunology from the medical faculty of the Université Claude Bernard Lyon II. Despite being in corporate for a good part of his career, Alfred is an entrepreneur at heart.

Alfred Chua

CEO
Biovalence

Alfred Chua

CEO
Biovalence

Dr. Alfred Chua was awarded a Colombo Plan scholarship by the Singapore government to read Veterinary Medicine in France at the Ecole Nationale Vétérinaire de Lyon. Alfred graduated with a degree in veterinary medicine in 1989 and returned to Singapore to serve his bond with the Agri-foods and Veterinary Authority of Singapore. He also a Diplomate in Immunology from the medical faculty of the Université Claude Bernard Lyon II. Despite being in corporate for a good part of his career, Alfred is an entrepreneur at heart.

Onsite Booklet
2019 Innovation Showcase Presenters + Sample Attendees
 

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem